Our mission: Advance precision psychiatry by introducing biology into clinical routine and accelerate access to treatment for people with bipolar disorder

Around 300M people in the world are affected by depression. Studies show that up to 40% of them may be misdiagnosed and potentially bipolar. As a result, diagnosis is often delayed by an average of 7.5 years, worsening patients’ mental and physical condition as well as their loved ones’ quality of life.

The EDIT-B Consortium aims to solve the bipolar disorder diagnostic challenge by using specific RNA editing based biomarkers and artificial intelligence to validate and commercialize a high performance and quick blood test to diagnose bipolar disorder.